Impact of early cART in the gut during acute HIV infection

Claire Deleage,1 Alexandra Schuetz,2,3 W. Gregory Alvord,4 Leslie Johnston,1 Xing-Pei Hao,5 David R. Morcock,1 Runsun Rerknimitr,5 James L.K. Fletcher,2,4 Suwanna Puttasawaswin,2,8 Nittaya Phanuphak,2,9 Robin Dewar,3 Joseph M. McCune,10 Irini Sereti,11 Merlin Robb,3 Jerome H. Kim,3,12 Timothy W. Schacker,13 Peter Hunt,14 Jeffrey D. Lifson,1 jintanat Ananworanich,3,7 and Jacob D. Estes1on behalf of the RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups15

1AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, Maryland, USA. 2Department of Retrovirology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. 3US Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA. 4Statistical Consulting, Data Management Services Inc., Frederick, Maryland, USA. 5Pathology and Histotechnology Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, Maryland, USA. 6Chulalongkorn University, Bangkok, Thailand. 7SEARCH, Bangkok, Thailand. 8Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 9Virus Isolation and Serology Laboratory, Applied and Developmental Research Directorate, Science Applications International Corp., Frederick Inc. National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, Maryland, USA. 10Division of Experimental Medicine, Department of Medicine, UCSF, San Francisco, California, USA. 11National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA. 12International Vaccine Institute, Seoul, South Korea. 13Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA. 14Positive Health Program, Department of Medicine, UCSF, San Francisco, California, USA. 15The RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups are detailed in the Supplemental Acknowledgments.

Introduction

The number of HIV-infected individuals receiving combination antiretroviral therapy (cART) has tripled in the last 5 years (1). Initiation of cART typically leads to a rapid and significant reduction in viral replication to the extent that the plasma HIV viral load becomes undetectable and the peripheral blood CD4+ T cell count increases in the majority of those who receive treatment. Nonetheless, HIV-infected individuals, particularly those who start cART at later stages of disease, are still afflicted with “non-AIDS” comorbidities and diseases, with a shorter life expectancy than age-matched, uninfected controls (2–5). It is hypothesized that persistent gastrointestinal (GI) tract damage despite cART leads to recurrent microbial translocation and contributes to sustained inflammation and immune activation, which are strongly associated with non-AIDS coinfections and comorbidities (6–9). Furthermore, recent data suggest that long-term cART does not readily reverse the extensive fibrotic damage to lymphoid tissues that is evident.
in HIV-infected individuals prior to cART initiation, particularly when treatment is started in the chronic phase of infection (10). Many of the non-AIDS morbidities are correlated with persistently elevated levels of immune activation and inflammation during HIV infection (11). Even though cART significantly decreases most of markers of immune activation and inflammation measurable in the blood, many studies have reported ongoing T cell activation and inflammation in tissues of patients undergoing long-term cART, which could be a result of persistent dysfunction and damage in the GI tract (6, 12, 13).

The GI tract is an organ system that is particularly affected by HIV infection. Substantial CD4+ T cell depletion in the GI tract occurs early during acute HIV infection (AHI) (14, 15), and, while some studies demonstrated partial recovery of CD4+ T cells following cART, these cells typically fail to be restored in the lamina propria (LP), the immune effector site of the GI tract (16). The reasons for the lack of reconstitution of CD4+ T cells in the LP of the GI tract are incompletely understood, but persistent GI tract damage and inflammation; loss of CD4+ central memory T cells, resulting in reduced production of CD4+ effector memory T cells; and residual ongoing HIV replication, despite the significant benefits of cART, may play a role (17, 18). While most studies have investigated the effects of cART in chronically HIV-infected (CHI) individuals, several studies have examined the potential benefits of administering cART during acute infection, finding that such an intervention is associated with the preservation immune function (19), limitation of the size of reservoir (20, 21), protection of long-lived cells from persistent infection (22), and enhanced recovery of CD4+ T cell numbers and function in blood (23, 24) and in the GI tract (25). However, it remains unclear whether early cART will prevent the loss of or restore CD4+ T cells within the LP effector site of the GI tract and limit or reverse the immunopathology associated with HIV-1 infection within the GI tract.

To examine these events more closely, we studied GI tract samples collected from the RV254/SEARCH 010 cohort in Thailand. Participants in this cohort were identified during early acute HIV-1 infection and immediately offered cART; they were also willing to undergo colonic biopsies (26, 27). This cohort represents a unique opportunity to investigate the effect of cART on the GI tract at the earliest time points clinically feasible after initial HIV infection. In this study, we compared the effects of cART initiated during acute or chronic phases of infection, specifically focusing on the immunopathology of the GI tract. We analyzed the effect of the timing of cART initiation on GI tract damage, the CD4+ T cell population size within the LP, and different aspects of immune activation and inflammation before and after 24 and 96 weeks of treatment.

**Results**

*Clinical characteristics and virological response to cART in plasma and colonic tissue.* We identified 41 individuals with AHI (Table 1), staged according to Fiebig classification (28), who were willing to undergo colonic biopsy. Eighteen participants were identified by pooled nucleic acid test (NAT) (nonreactive HIV IgM antibody) and classified as Fiebig I/II (FI/II), and 23 were identified by sequential enzyme immunoassay (EIA) (reactive HIV IgM/non-reactive HIV IgG antibody) and classified as Fiebig III–V (FIII+) (28). Additionally, 10 age-, gender-, and risk group-matched HIV-uninfected (HIV−) individuals from Thailand served as negative controls, and 16 CHI individuals (6 of which were from Thailand and received treatment in the chronic phase of the infection and 10 of which were from the US and were untreated) were included to serve as positive controls. Participants were mainly young men who have sex with men (73%) infected with HIV-1 CRF01_AE (30 of 41), with a median time since history of HIV-1 exposure of 15 days (range 4–32), a median CD4+ T cell count of 466 cells/mm³ (Figure 1A), a median plasma HIV RNA load of 5.51 log₁₀ copies/ml (Figure 1B), and a median colon HIV RNA load of 2.85 log₁₀ copies/mg tissue (Figure 1C). The plasma as well as the colonic HIV RNA load increased significantly with progression of infection from FI/II to treatment (plasma HIV RNA: FI/II 4.97 log₁₀ copies/ml vs. FIII+ 5.63 log₁₀ copies/ml; P = 0.002; colonic HIV RNA: FI/II 1.98 log₁₀ copies/mg tissue vs. treatment 3.12 log₁₀ copies/mg tissue; P = 0.01) (Figure 1, B and C).

We determined the anatomical localization of productively infected HIV viral RNA+ (vRNA+) cells by performing standard in situ hybridization using lineage-specific riboprobes to either HIV-1 CRF01_AE or HIV-1 clade B. Many patients with AHI FI/II had abundant vRNA+ cells in both the LP and lymphoid aggregates (Figure 1D), highlighting the early detection of these individuals. By contrast, in the later FIII+ acute phase, HIV-1 vRNA+ cells were absent from the LP and restricted to the lymphoid aggregates (Figure 1D), consistent with rapid depletion of CD4+ T cells within the LP.
After the initiation of cART, the median peripheral blood CD4⁺ T cell count increased to 591 cells/mm³ at week 24 and to 617 cells/mm³ at week 96 for all groups (Figure 1E). Plasma HIV-1 RNA decreased below 30 copies/ml, reaching an undetectable level in 98% (40 of 41) of patients tested at week 24 and 95% (39 of 41) at week 96 (Figure 1F). By 24 weeks of cART, HIV-1 RNA levels in gut tissue were below 50 copies/mg tissue in 90% (28 of 31) of the participants tested (Figure 1G). After only 24 weeks of treatment, we were not able to detect any vRNA+ cells by standard in situ hybridization in colonic biopsies from any of the AHI or CHI participants placed on cART during AHI or CHI (data not shown).

GI tract epithelial barrier integrity, early GI tract damage, inflammation/immune activation, and CD4⁺ T cell depletion during AHI. We sought to determine whether participants identified after AHI would have evidence for CD4⁺ T cell depletion in the LP of the GI tract. During AHI, there was a significant decrease in CD4⁺ T cells within the LP in both FI/II and FIII+ patients compared with HIV – individuals (percentage area CD4⁺ T cells in LP, FI/II: 1.35% and FIII+: 0.62% vs. HIV –: 2.14%; \( P = 0.0076 \) and \( P < 0.0001 \), respectively) (Figure 2), consistent with our previous observations (25). The FIII+ group had more severe depletion of CD4⁺ T cells; it was significantly lower than that found in the FI/II group at baseline (percentage area CD4⁺ T cells in LP, FI/II: 1.35% vs. FIII+: 0.62%; \( P = 0.005 \)). As expected, the CD4⁺ T cell population size was significantly decreased in untreated patients with CHI compared with HIV – individuals (percentage area CD4⁺ T cells in LP CHI no cART: 0.894% vs. HIV –: 2.14%; \( P = 0.001 \)) (Figure 2). In contrast to CD4⁺ T cells, myeloid lineage cell populations (CD68⁺/CD163⁺) were not significant different between any of the groups (data not shown), highlighting the specificity of the CD4⁺ T cell loss within the

<table>
<thead>
<tr>
<th>Table 1. Clinical baseline characteristics and demographics of study participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristics</td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>Median age (yr)</td>
</tr>
<tr>
<td>Gender: female/male</td>
</tr>
<tr>
<td>Risk behavior, n (%)</td>
</tr>
<tr>
<td>MSM</td>
</tr>
<tr>
<td>Bisexual male</td>
</tr>
<tr>
<td>Fiebig stage, n</td>
</tr>
<tr>
<td>I</td>
</tr>
<tr>
<td>II</td>
</tr>
<tr>
<td>III</td>
</tr>
<tr>
<td>V</td>
</tr>
<tr>
<td>VI</td>
</tr>
<tr>
<td>Coinfection, STI</td>
</tr>
<tr>
<td>Mean (SD) duration of HIV (d)</td>
</tr>
<tr>
<td>Median HIV RNA (log₁₀ copies/ml)</td>
</tr>
<tr>
<td>Plasma d0</td>
</tr>
<tr>
<td>Colonic d0</td>
</tr>
<tr>
<td>Median CD4 count (cell/mm³)</td>
</tr>
<tr>
<td>d0</td>
</tr>
<tr>
<td>24 weeks</td>
</tr>
<tr>
<td>96 weeks</td>
</tr>
<tr>
<td>HIV subtype by MHAbce(^a)</td>
</tr>
<tr>
<td>CRF01_AE</td>
</tr>
<tr>
<td>Recombinant AE/B</td>
</tr>
</tbody>
</table>
| Minimum value, maximum value. \(^a\)MHAbce, multiregion hybridization assay distinguishing between subtypes B, C and CRF01_AE. One participant was CRF01_AE/B, six were nontypable (NT) and three were not determined by the time we were writing the manuscript; MSM, men who have sex with men; Fiebig I, positive HIV RNA, negative p24 antigen, negative third generation EIA; Fiebig II, positive HIV RNA, positive p24 antigen, negative third generation EIA; Fiebig III, positive HIV RNA, positive p24 antigen, positive third generation EIA, negative Western blot; Fiebig IV, positive HIV RNA, positive or negative p24 antigen, positive third generation EIA, indeterminate Western blot; Fiebig V, positive HIV RNA, positive p24 antigen, positive third generation EIA, positive Western blot except p31; NA, not applicable; STI, sexually transmitted infection; HBV, hepatitis B virus.
LP of HIV-infected individuals. While the number of CD8+ T cells in the FI/II group was not significantly increased compared with the HIV− individuals (mean percentage area of CD8+ T cells in LP AHI, FI/II: 5.32% vs. HIV−: 4.69%; P = 0.2) (data not shown), the FIII+ group showed a significant increase in CD8+ T cells compared with both FI/II patients and HIV− individuals (mean percentage area of CD8+ T cells in LP AHI, FIII+: 6.82% vs. FI/II: 5.32%, HIV−: 2.14%; P = 0.09 and P = 0.04, respectively). However, the CD8+ T cell level remained lower in both Fiebig groups compared with untreated participants with CHI (mean percentage area of CD8+ T cells in LP AHI, FI/II: 5.32%, FIII+: 6.82% vs. CHI: 10.4%; P = 0.004 and P = 0.02, respectively). Collectively, these data highlight the dynamic and progressive nature of CD4+ T cell depletion and adaptive T cell responses in the LP of the GI tract during HIV infection.

Next, we sought to determine whether participants identified at early stages of HIV infection had limited GI tract epithelial damage and, as a result, limited microbial translocation. In a SIV-infected nonhuman primate (NHP) model, such damage is first evident late in the acute phase of infection (i.e., 14 dpi) (29). In humans, however, mucosal barrier integrity and microbial translocation are inherently difficult to evaluate and quantify in small GI tract pinch biopsies, due to the process of biopsy collection, which can result in the physical disruption of the epithelial barrier by the forceps during the biopsy procedure itself and due to the small size and orientation of the biopsies. We have demonstrated, however, that a local tissue response consisting of the infiltration of polymorphonuclear neutrophils (PMNs) in the LP of the GI tract is an excellent surrogate marker for epithelial damage and local microbial translocation (6, 29, 30). Therefore, using immunohistochemistry and quantitative image analysis, we analyzed GI tract damage by measuring the extent of myeloperoxidase+ (MPO+) PMNs within the LP (Figure 3). We observed a significant increase in the abundance of PMNs in FI/II patients compared with HIV− individuals (mean percentage area of PMNs in LP AHI, FI/II: 0.26% vs. HIV−: 0.032%; P = 0.017) and in the FIII+ patients compared with HIV− individuals (mean percentage area of PMNs in LP AHI, FIII+: 0.16% vs. HIV−: 0.032%; P = 0.0076) (Figure 3A). As expected, the number of PMNs in the LP of untreated chronically infected individuals was much higher than that found in the context of CHI (mean percentage area of PMNs in LP AHI, FI/II: 0.26% vs. CHI: 0.93%; P = 0.001 and FIII+: 0.16% vs. CHI: 0.93%; P = 0.0004).

We next investigated the extent of local immune activation within the LP of the GI tract by measuring the total cells that were Ki-67+ in the LP (Figure 4, A and B). During AHI, there was a significant increase in Ki-67+ cells in the FIII+ group compared with HIV− individuals (mean percentage area of Ki-67+ cells in LP AHI, FIII+: 2.90% vs. HIV−: 1.05%; P < 0.0001) and with chronically infected individuals (both cART treated and untreated) compared with HIV− individuals (mean percentage area of Ki-67+ cells in LP, CHI treated: 1.99%, CHI untreated: 4.18% vs. HIV−: 1.05%; P = 0.049 and P < 0.0001, respectively) (Figure 4A). We observed a slight increase between AHI FI/II and HIV− individuals, but this difference was not statistically significant. Consistent with the early identification of FI/II individuals, the number of Ki-67+ cells in the FIII+ group was significantly higher than that observed in the FI/II group (mean percentage area of Ki-67+ cells in LP, AHI FIII+: 2.90% vs. AHI FI/II: 2.18; P = 0.0024).

We next determined the extent of local GI tract inflammation by quantifying (as the percentage area of the LP) the expression of the proinflammatory cytokine, TNF-α (Figure 4C); the type I IFN-responsive gene product, Mx1 (Figure 4D); IL-17 (Figure 4E); and indoleamine 2,3-dioxygenase-1 (IDO-1) (Figure 4F) during AHI. The number of TNF-α+ cells was significantly increased during AHI compared with levels seen in HIV− individuals (mean percentage area of TNF-α+, FI/II: 0.38%, FIII+: 0.47% vs. HIV−: 0.1%; P = 0.0006 and P = 0.0005, respectively). While the expression of Mx1 was heterogeneous within the
RESEARCH ARTICLE

different AHI groups, it was clearly elevated compared with levels found in HIV– individuals (mean percentage area of Mx1+ cells: FI/II: 6.67%, FIII+: 2.52% vs. HIV–: 0.08%; \( P = 0.002 \) and \( P = 0.0004 \), respectively). The expression of IL-17 in participants with AHI was unchanged compared with HIV– individuals (mean percentage area of IL-17+ cells in LP, AHI FI/II: 1.30%, FIII+: 1.09% vs. HIV–: 1.21%; \( P = 0.760 \) and \( P = 0.670 \), respectively) (Figure 4E). However, untreated participants with CHI had significantly higher expression of total IL-17 in the LP compared with FI/II and FIII+ groups (mean percentage area of IL-17+ cells in LP, AHI FI/II: 1.30%, AHI FIII+: 1.09% vs. CHI: 2.07%; \( P < 0.001 \), \( P < 0.001 \), respectively).

Since inflammation and type I IFNs can also induce immunomodulatory enzymes such as the tryptophan-catabolizing enzyme, IDO-1, we quantified IDO-1 expression in the LP (Figure 4F) and observed an increase in CHI patients and in the FI/II and FIII+ groups compared with HIV– individuals (percentage area of IDO-1 cells in LP, AHI FI/II: 1.30%, AHI FIII+: 1.09% vs. CHI: 2.07%; \( P < 0.001 \), \( P < 0.001 \), respectively). Since inflammation and type I IFNs can also induce immunomodulatory enzymes such as the tryptophan-catabolizing enzyme, IDO-1, we quantified IDO-1 expression in the LP (Figure 4F) and observed an increase in CHI patients and in the FI/II and FIII+ groups compared with HIV– individuals (percentage area of IDO-1 cells in LP, AHI FI/II: 1.30%, AHI FIII+: 1.09% vs. CHI: 2.07%; \( P < 0.001 \), \( P < 0.001 \), respectively).

Collectively, these data highlight the dynamic and progressive nature of host immune responses and pathology in the GI tract during AHI.

Effect of early cART during AHI on GI tract damage, inflammation/immune activation, and CD4+ T cell reconstitution. After the initiation of cART, we observed a decrease of PMNs cells in the LP of individuals in the FI/II group; however, this was not statistically significantly, likely due to the low number of patients followed through 96 weeks of cART (mean percentage area PMNs in LP AHI FI/II, week 0: 0.26% vs. week 24 cART: 0.05%; week 96 cART: 0.089%, \( P = 0.095 \) and \( P = 0.303 \), respectively) (Figure 5, A and C). We observed some variation among participants in the PMN number after treatment (Figure 5, B and D). Of the 15 patients who had biopsies that could be evaluated for PMN infiltration at the 3 visits (week 0, 24, and 96), 8 had a significant decrease in their colonic PMN numbers (with slopes from –0.137 to –1.693, \( P = 0.0006 \) to \( P = 0.0148 \)). The other 7 patients either had PMN numbers that were unchanged (\( n = 5 \)) or increased (\( n = 2 \)) during follow-up. Taken together, these results did not show a significant decrease in GI

---

**Figure 2. CD4+ T cells in the lamina propria of acute HIV-infected participants.** Sigmoid biopsies were stained for CD4 (brown) and CD68/CD163 (red). The CD4+ T cell population is determined by subtraction of the myeloid population (red) from the total CD4+ cell population. The percentage area of the lamina propria (LP) that stained for CD4+ T cells was quantified in HIV– (\( n = 10 \)), HIV chronic (\( n = 16 \)), Fiebig I/II (FI/II) (\( n = 19 \)), and Fiebig III–V (FII+) (\( n = 22 \)) patients at the first visit (A). FI/II patients presented varying levels of depletion, while the FIII+ participants manifested a drastic decrease of the CD4+ T cells in the LP at the first visit. Representative images for HIV control, HIV chronic, and the different Fiebig groups are shown in B. Each point represents the median of a minimum of 3 quantified biopsies per participant. Within the chronic patients, the open squares indicate untreated participants and the closed squares indicate treated participants. Within the FI/II group, lighter blue dots represent FI patients and darker blue dots represent the FII patients. Within FIII+ group, lighter blue dots represent FIII+ patients and darker blue dots represent FIV and FV patients. Scale bar: 100 μm. Following linear mixed-effects (lme) analyses, post-hoc lme contrasts and pairwise nonparametric (Wilcoxon) tests were performed. Benjamin-Hochberg adjusted \( P \) values are reported. Data are presented as box-and-whisker plots with the lower and upper limits (bounds) of the box representing Q1 (25th percentile) and Q3 (75th percentile), respectively. The median (Q2, 50th percentile) is represented by the horizontal line within the box. Whiskers, delineated as horizontal stems, extend to the limits of the data. Data points (superimposed) are “jittered” to avoid overplotting.
tract damage, as measured by PMN infiltration, in either AHI Fiebig groups after cART treatment ($P = 0.375$). While the number of PMNs did not significantly decrease over the 96 weeks of follow-up in the FI/II group, the number of PMNs at week 96 was not significantly different compared with the HIV– individuals (mean percentage area PMNs in LP, HIV–: 0.03% vs. AHI FI/II week 96: 0.089%, $P = 0.081$); however, there was still a significant difference when comparing the FIII+ group at week 96 with the HIV– individuals (mean percentage area of PMNs in LP HIV–: 0.03 vs AHI FIII+: 0.30, $P = 0.027$). The elevated mean percentage area of PMNs in the FIII+ group at week 96 was driven by one patient who had much higher numbers of PMNs (percentage area PMNs in LP: 1.71%) compared with the remaining FIII+ individuals (mean percentage area of PMNs in LP: 0.10% with patient removed, mean percentage area PMNs in LP HIV–: 0.03% vs. AHI FIII+: 0.10%, $P = 0.027$). Importantly, the patient with the elevated PMN levels at week 96 cART also had a positive viral load at this time point, suggesting treatment failure and recurrent GI tract damage. Collectively, these data suggest that early cART may lead to an improvement in GI tract integrity in patients who adhere to their medications; however, damage may persist even after 96 weeks of treatment in some patients.

Next, we sought to ascertain the effect of cART on levels of immune activation and inflammation within the LP of the large intestine (Figure 6). After 24 weeks of treatment, the number of Ki-67+ cells significantly decreased in both Fiebig groups ($P = 0.016$), reaching baseline levels after 96 weeks of cART compared with uninfected individuals (mean percentage area of Ki-67+ cells in LP AHI, week 96 cART FI/II: 1.05%, week 96 cART FIII+: 0.98% vs. HIV–: 1.05%, $P = 0.887$ and $P = 0.668$, respectively) (Figure 6, A and B). To determine the effect of cART on levels of inflammation within the LP, we first quantified the number of cells that were expressing the proinflammatory cytokine, TNF-α. After the initiation of cART, the number of TNF-α+ cells decreased in the FI/II group (mean percentage area of TNF-α+ cells FI/II at week 0: 0.38% vs. week 24: 0.08% and week 96: 0.17; $P = 0.0065$ and $P = 0.020$, respectively) (Figure 6C).

Figure 3. Increased gastrointestinal tract damage in early acute HIV-infected patients. Sigmoid biopsies were stained for myeloperoxidase (MPO), and the percentage area of neutrophils at the first visit was quantified. Each point represents the median percentage area of the lamina propria (LP) occupied by neutrophils quantified in a minimum of 3 biopsies for each participant. Notice the significant increase of neutrophils in Fiebig I/II (FI/II) ($n = 18$) and Fiebig III–V (FIII+) ($n = 22$) patients compared with HIV– controls ($n = 10$) (A). Representative images of MPO-stained biopsies of HIV– control, FI/II, and FIII+ participants are shown in B. Each point represents the median of a minimum of 3 quantified biopsies per participant. Within the chronic patient ($n = 16$), the open squares indicate untreated participants and the closed squares indicate treated participants. Within the FI/II group, lighter blue dots represent FI patients and darker blue dots represent the FII patients. Within FIII+ group, lighter blue dots represent FIII+ patients and darker dots represent FIV and FV patients. Scale bar: 100 μm. Following linear mixed-effects (lme) analyses, post-hoc lme contrasts and pairwise nonparametric (Wilcoxon) tests were performed. Benjamini-Hochberg adjusted p values are reported. Data are presented as box-and-whisker plots with the lower and upper limits (bounds) of the box representing Q1 (25th percentile) and Q3 (75th percentile), respectively. The median (Q2, 50th percentile) is represented by the horizontal line within the box. Whiskers, delineated as horizontal stems, extend to the limits of the data. Data points (superimposed) are “jittered” to avoid overplotting.
The FIII+ group, by contrast, did not show significant changes in TNF-α expression until 96 weeks of treatment ($P = 0.020$). After 96 weeks of cART, the number of TNF-α+ cells went back to levels similar to those of HIV– individuals for both AHI groups (mean percentage area of TNF-α+ cells at week 96 cART, FI/II: 0.17%, FIII+: 0.10% vs. HIV–: 0.10%; $P = 0.089$ and $P = 0.058$, respectively) (Figure 6, C and D).

To further assess the effect of cART on levels of inflammation within the LP, we quantified the number of cells that were expressing the type I IFN-responsive gene product, Mx1. The number of Mx1+ cells decreased significantly after the initiation of cART in both Fiebig groups (mean percentage area of Mx1+ cells at week 0 cART, FI/II: 6.67%, FIII+: 2.52% vs. FI/II week 24: 0.07% and FIII+ week 24: 0.13%; $P = 0.0073$ and $P = 0.0074$, respectively) (Figure 6, E and F). The resolution of type I IFN inflammation appeared quite rapid, as after 24 weeks of treatment the number of Mx1+ cells had returned to levels comparable to those of the HIV– individuals for both Fiebig groups (mean percentage area of Mx1+ cells, FI/II week 24: 0.07% and FIII+ week 24: 0.13% vs. HIV–: 0.08%; $P = 0.078$ and $P = 0.18$, respectively). The expression of IL-17 in the LP, on the other hand, did not change from week 0 of cART for either the FI/II (mean percentage area of IL-17+ cells in LP, week 0 FI/II: 1.10%, week 24 cART: 1.10%, week 96 cART: 1.0%; $P = 0.485$ and $P = 0.386$, respectively) or FIII+ groups (week 0 FIII+: 1.07%, week 24 cART: 1.6%, and week 96 cART: 1.3%; $P = 0.264$ and $P = 0.690$, respectively) (Figure 6, G and H).

Finally, we assessed the effect of early cART on CD4+ T cell levels in the LP in our AHI cohort. After 24 weeks of cART, the number of CD4+ T cells in the LP was significantly decreased in FI/II individuals compared with week 0 (mean percentage area of CD4+ T cells in LP FI/II, week 0: 1.35% vs. week 24 cART: 0.56%; $P = 0.0078$) (Figure 7A). However, the FIII+ individuals showed no significant difference after 24 weeks of cART compared with week 0 (mean percentage area of CD4+ T cells in LP, week 0: 0.62% vs. week 24 cART: 0.52%; $P = 0.672$) (Figure 7B). Importantly, while after 96 weeks of cART, FI/II individuals showed a modest but significant increase in the number CD4+ T cells in the LP compared with the 24 week cART time point (mean percentage area of CD4+ T cells in LP week 24 cART: 0.56% vs. 96 week cART: 0.89%; $P = 0.0306$), the number of CD4+ T cells at 96 weeks of cART was, however, still marginally significantly lower than that found in HIV– individuals (mean percentage area of CD4+ T cells in LP FI/II week 96 cART: 1.36% vs. HIV–: 2.14%; $P = 0.043$) (Figure 7A). By contrast, the number of CD4+ T cells in the LP of the FIII+ group between 24 and 96 weeks of cART (mean percentage area of CD4+ T cells in LP, week 24 cART: 0.51% vs. week 96 cART: 0.89%; $P = 0.31$) and after 96 weeks of cART (mean percentage area of CD4+ T cells in LP FIII+ week 96 cART: 0.89% vs. HIV–: 2.14%; $P = 0.0001$) continued to be significantly lower compared with that found in HIV– individuals (Figure 7B). Furthermore, at 96 weeks of cART, the FI/II individuals showed a significant difference in the number of CD4+ T cells in the LP compared with the FIII+ group (mean percentage area of CD4+ T cells in LP, week 96 cART FI/II: 1.36 vs. week 96 cART FIII+: 0.89; $P = 0.04$), suggesting an incremental benefit for very early cART treatment. Finally, after initiation of the treatment, the abundance of myeloid lineage cells within the LP did not change in any group (data not shown).

**Discussion**

GI tract pathologies, including early depletion of CD4+ T cells in the LP and damage to the GI tract epithelial barrier, are known to be characteristic of HIV-1 infection (13). We initially hypothesized that such effects might be mitigated by the early initiation of cART, reasoning that control of viral replication at the earliest time point clinically feasible would have a positive effect on the loss of CD4+ T cells in the effector sites of GI tract tissues. We accordingly investigated the effect of early initiation of cART in acute HIV-1-infected patients in Thailand enrolled in the RV254 study.
Here, we demonstrate that individuals identified during early AHI already had extensive evidence of GI tract pathologies, including GI tract damage, associated inflammation, and immune activation, and the loss of CD4+ T cells from the LP effector site of the GI tract. These data are consistent with previous observations made in SIV-infected nonhuman primates (31–33) and suggest (a) that the pathologic effects of HIV-1 infection in the GI tract begin remarkably early during acute infection and (b) that these initial effects are not preventable, even when cART is commenced at the very earliest feasible time point clinically. Notwithstanding these sobering facts, it is highly encouraging that cART does result in reversal of many other key features of early GI tract pathology, including resolution of GI tract inflammation and immune activation, and GI tract epithelial damage with microbial translocation in some patients (as measured by neutrophil infiltration). Notably, these are features that persist in many HIV-infected individuals who are treated later in the disease course (6, 7, 34, 35). The importance of restoring GI tract integrity and attenuating GI tract inflammation in patients treated in early acute infection may help explain why patients identified and treated at the earliest Fiebig stages have reduced HIV reservoirs (36, 37), particularly since residual inflammation during cART is thought to be a critical driver of HIV persistence (38). Thus, reducing inflammation may be an effective way to obstruct the maintenance of HIV reservoirs in cART-suppressed individuals.

It is important to note that we identified several individuals during the early FI/II stage who did not have evidence for CD4+ T cell depletion in the LP prior to cART but who did subsequently show CD4+ T cell depletion after 24 weeks of cART. These data suggest that cART intervention simply cannot be feasibly administered quickly enough to prevent the early consequences of HIV-1–mediated destruction of CD4+ T cells within the LP effector compartment of the gut. Indeed, while our previous analysis of many of these individuals suggested significant CD4+ T cell recovery in the GI tract, as assessed by flow

---

**Figure 5. Longitudinal quantification of damage to the gastrointestinal tract after 24 and 96 weeks of antiretroviral treatment.** Sigmoid biopsies were stained for myeloperoxidase (MPO) as a surrogate marker of the mucosal damage in Fiebig I (FI) and II (FII) participants (week 0, n = 18) (A) and in Fiebig III (FIII) and IV/V (FIV/V) patients (week 0, n = 22) (B) 24 (FI/II and FIII+, n = 13) and 96 weeks (FI/II, n = 7; FIII+, n = 13) after the initiation of combination antiretroviral therapy (cART). Each symbol represents a patient. FII is distinguishable from FI by the light-blue colored symbols, and FIV/V is distinguishable from FIII by the dark-blue colored symbols. Representative images of FI participants at 24 weeks and 96 weeks after treatment are shown in C. One Fiebig V patient showed an increase of neutrophils at 96 weeks (D); this patient had a detectable blood viral load at this same time point. Each point represents the median of a minimum of 3 quantified biopsies per participant. Scale bar: 100 μm. Following repeated-measures and linear mixed-effects (lme) analyses, post-hoc lme contrasts and pairwise nonparametric (Wilcoxon) tests were performed. Benjamini-Hochberg adjusted P values are reported.
cytometry (25), we demonstrate here by histological evaluation that CD4+ T cell levels in the LP effector site of the GI tract did not return to normal in most individuals treated during early AHI. This dichotomy suggests that the previously observed increases occurred within lymphoid tissue structures (e.g., lymphoid aggregates) and not within the effector sites of the gut. This is in concordance with several previous studies demonstrating that CD4+ T cells in the GI tract remained significantly lower than in HIV− controls, despite effective prolonged cART (14, 39–43). It is encouraging to note that several individuals treated during FI/II approached HIV− baseline CD4+ T cell levels in the LP and demonstrated significant increases in CD4+ T cells from the 24 to 96 week time point. Although additional follow up will be required to definitively determine the extent to which such recovery occurs in this cohort, this observation suggests that CD4+ T cell reconstitution may be possible at least in some individuals treated early.

Numerous studies have reported the importance of IL-17A in neutrophil recruitment, proliferation of epithelial cells, and production of epithelial tight junction proteins and antimicrobial defensins (44, 45). IL-17A is produced by numerous cells, including Th17 CD4+ T cells, and has been shown to be drastically decreased in the gut of HIV-1 chronically infected patients (46). The loss of multiple lineages of IL-17-producing lymphocytes, including Th17 CD4+ T cells that are critical for the maintenance of gut epithelial barrier integrity, has been associated with damaged mucosal barrier and microbial translocation as well as dysfunctional local innate and adaptive immune functions and disease progression (47–50). In this study, we were unable to measure IL-17A specifically, given that the polyclonal antibody used has been demonstrated to have some cross-reactivity to other IL-17 isoforms (notably IL-17F and to a lesser extent IL-17C, D and E). Nonetheless, we did not observe a decrease of total IL-17 expression in the LP of the GI tract during AHI in either Fiebig group, a finding consistent with those in our previous study utilizing flow cytometry to assess T cell population changes (25) and in a more recent study (51). The lack of loss of IL-17+ cells in FIII+ patients in our current study compared with the initial loss of Th17 cells reported in our previous study (25) could also be explained by the fact that IL-17A is produced by numerous cell types other than Th17 cells, e.g., CD8+ T cells, T cells, NK cells, NKT cells, LTi, neutrophils, and Paneth cells (52). Alternatively, early treatment with cART may result in the preservation of CD103+ DCs within the LP of the large intestine, as loss of such cells has been associated with the loss of IL-17- and IL-22-producing lymphocytes (50); however, due to limited biopsy size and sampling, we were unable to investigate this possibility. These results suggest that compensatory and/or redundant mechanisms exist for IL-17 expression and may be important for the resolution that we observed in the mucosal barrier of the gut.

The mechanisms for the lack of CD4+ T cell recovery in the LP are not fully understood but may be due in part to collagen deposition in the gut-inductive sites (53) and/or to the loss of expression of gut-homing receptors on circulating CD4+ T cells (42, 54). While additional studies will be required to completely understand the mechanisms and the clinical implications of continued CD4+ T cell depletion in the setting of cART, we did observe significantly decreased levels of local inflammation and immune activation in the GI tract with early cART treatment. Several previous studies have reported a decrease in peripheral T cell activation (55, 56) and a variety of plasma biomarkers of inflammation (36, 57, 58) in individuals treated during acute infection; by inference, such changes might be associated with a reduced rate of disease progression and a decreased risk of non-AIDS comorbidities compared with those who initiate cART at a later time after infection (13, 59–62). If so, attenuation of GI tract pathologies could have a positive effect on the overall health of HIV-infected individuals treated early during AHI, as these individuals would be predicted to have fewer non-AIDS comorbidity events, with improved clinical outcomes linked to a better quality of life and life expectancy compared with individuals starting treatment later (63, 64).
Methods

Study participants. The RV254/SEARCH 010 study is an ongoing prospective, open-label study based in Bangkok, Thailand (clinicaltrials.gov identification NCT00796146). Blood samples from participants from clients from the Thai Red Cross Anonymous Clinic and the Silom Community Clinic were screened in real time by pooled NAT and sequential EIA, according to published methods (65). Participants who had positive NAT and nonreactive HIV IgG were enrolled in the RV254 cohort. Gut biopsies were performed by sigmoidoscopy on a volunteer basis (including 41 participants at baseline [before ART], 27 at 24 weeks after ART, and 18 at week 96 after ART). cART was initiated as part of enrollment in an accompanying local protocol (clinicaltrials.gov identification NCT00796263) approved by the Chulalongkorn University IRB. Treatment was started as soon as possible after enrollment (range 0–5 days). Subsequently, participants were randomized to 5-drug (MegaHAART, including tenofovir [TDF], emtricitabine [FTC] or lamivudine [3TC], efavirenz [EFV], raltegravir [RAL], and maraviroc [MVC]) ART vs. 3-drug (HAART with TDF , FTC/3TC, and EFV) ART. The 5-drug regimen was given as followed for the first 24 weeks: TDF , 300 mg once daily; FTC, 200 mg once daily, or 3TC, 300 mg once daily; EFV, 600 mg once daily; RAL, 400 mg twice daily; and MVC, 600 mg twice daily; this was followed by simplification to 3 drugs, i.e., TDF, FTC/3TC, and EFV. In case of intolerance or resistance, EFV was discontinued, and the dose of MVC was adjusted to 300 mg twice daily. Patients were initially screened for potential coinfections and at the time of each biopsy. In the FI/II group, at enrollment, 1 participant had gonorrhea proctitis, 4 had syphilis, and 2 were diagnosed with hepatitis B virus (HBV) infection. In the FIII+ group, 6 participants had syphilis and 1 had genital herpes at enrollment; another 2 participants had gonorrhea infection at 16 weeks and 24 weeks after enrollment. It is important to note that all participants with HBV infection received TDF and 3TC or FTC per the standard of care in Thailand. All study participants signed informed consent prior to study enrollment.

Diagnosis of AHI. Diagnosis of AHI was performed as described previously (25, 36). In brief, Thai AHI participants were enrolled if they fulfilled laboratory criteria for Fiebig stages I–V (28) as follows: FI: positive HIV RNA, negative p24 antigen, negative third generation IA; FII: positive HIV RNA, positive p24 antigen, negative third generation IA; FIII: positive third generation IA, negative Western blot; FIV: positive third generation EIA, indeterminate Western blot; and FV: positive third generation IA, positive Western blot except p51.

vRNA quantification in plasma and tissue. HIV RNA in plasma was measured using the Roche Amplicor v 1.5 ultrasensitive assay with a lower quantification limit of 50 copies/ml (Roche Diagnostics). For gut
Tween-20, endogenous peroxidases were blocked using 1.5% (v/v) H2O2 in TBS, pH 7.4, for 5 minutes, and

tems, catalog AF-317-NA) diluted in blocking buffer or TBS-tween. After washing in 1× TBS with 0.05%
A0398), rabbit anti-IDO-1 (1:1,000; Millipore, catalog Ab9098), or goat anti-IL-17A (1:100; R&D Sys-

tics, catalog AF-317-NA) diluted in blocking buffer. For all other antibodies, slides were incubated overnight at 4°C with rabbit

anti-CD8 mAb (1:100; ThermoFisher Scientific, catalog MA1-39566, clone SP16), rabbit anti-Ki-67 mAb

diluted in blocking buffer. For all other antibodies, slides were incubated overnight at 4°C with rabbit

anti-TNF-α, Mx1, and CD8

heat-induced epitope retrieval was performed by heating sections in 0.01% citraconic anhydride containing 0.05% Tween-20 for TNF-α, Mx1, and CD8 and 1× DIVA for Ki-67 and IL-17 or citrate pH 6.0 for MPO in a pressure cooker set at 122°C or 125°C for 30 seconds. Slides were incubated with blocking buffer (TBS with 0.05% Tween-20 and 0.25% casein) for 20 minutes. For TNF-α and Mx1, slides were incubated for 1 hour at room temperature with mouse anti-TNF-α mAb (1:100; Abcam, catalog ab9579, clone P/T2) or with mouse anti-Mx1 mAb (1:2,000; a gift from Georg Kochs and the Department of Virology of the University of Freiburg, clone M143) diluted in blocking buffer. For all other antibodies, slides were incubated overnight at 4°C with rabbit

anti-CD68/CD163 to quantify CD4+ T cells was performed as described previously (67). This multistaining approach allows the intense

dewaxed and rehydrated with double-distilled water. Multistaining of CD4/CD68/CD163 to quantify

Heat-induced epitope retrieval was performed as previously described (66). In brief, immunohistochemistry was performed using a biotin-free polymer approach (Golden Bridge International) on 5-μm tissue sections mounted on glass slides, which were

dewed and rehydrated with double-distilled water. Multistaining of CD4/CD68/CD163 to quantify CD4+ T cells was performed as described previously (67). This multistaining approach allows the intense staining of the macrophage/myeloid cell markers to mask the faint CD4 expressed on these cells and to distinctly identify CD4+ T cells from myeloid lineage cells. Heat-induced epitope retrieval was performed by heating sections in 0.01% citraconic anhydride containing 0.05% Tween-20 for TNF-α, Mx1, and CD8 and 1× DIVA for Ki-67 and IL-17 or citrate pH 6.0 for MPO in a pressure cooker set at 122°C or 125°C for 30 seconds. Slides were incubated with blocking buffer (TBS with 0.05% Tween-20 and 0.25% casein) for 20 minutes. For TNF-α and Mx1, slides were incubated for 1 hour at room temperature with mouse anti-TNF-α mAb (1:100; ThermoFisher Scientific, catalog MA1-39566, clone SP16), rabbit anti-Ki-67 mAb (1:200; ThermoFisher Scientific, catalog RM-9106, clone SP6), rabbit anti-MPO (1:5,000; Dako, catalog A0398), rabbit anti-IDO-1 (1:1,000; Millipore, catalog Ab9098), or goat anti-IL-17A (1:100; R&D Systems, catalog AF-317-NA) diluted in blocking buffer or TBS-tween. After washing in 1× TBS with 0.05% Tween-20, endogenous peroxidases were blocked using 1.5% (v/v) H2O2 in TBS, pH 7.4, for 5 minutes, and the slides were incubated with rabbit or mouse Polink (-1 or -2) horseradish peroxidase and developed with ImmPACT DAB (3,3′-diaminobenzidine; Vector Laboratories), according to the manufacturer’s recommendations. All slides were washed in tap water, counterstained with hematoxylin, mounted in Permount (Fisher Scientific), and scanned at high magnification (×200) using the ScanScope CS or AT2 System (Aperio Technologies), yielding high-resolution data from the entire tissue section. Representative regions of interest (500 × 500 μm) were identified and high-resolution images were extracted from these whole-tissue scans. The percentage area of the positive cell zone was quantified using Photoshop CS5 and Fovea tools.

**HIV-1 clade A/E lineage-specific in situ hybridization.** To ensure optimal detection of productively infected cells from HIV-infected participants from Thailand, we designed a new set of HIV-1 clade A/E lineage-specific in situ hybridization riboprobe for these experiments. HIV-1 clade A/E riboprobes were generated by PCR-based cloning of target regions from the full-length infectious molecular clone pCM235 from Thailand (accession no. AF299954), provided by George Shaw (University of Pennsylvania, Philadelphia, Pennsylvania, USA). Riboprobes were generated targeting Gag (1,454–1,958; GAG F1454: 5′-CCAGTACATG-CAGGGCCTAT and GAG R1958: 5′-GGGCCCTTTAAATGCTTCTC), Pol (3,998–4,570; POL F3998: 5′-ATGCGATCCATTAGCCTTG and POL R4570: 5′-TTACTG GCCATCTTCTGCT), the accessory genes Vif/Vpr/Vpu/Tat/Rev (5,287–5,825; VIF-REV F5782: 5′-GGAAATTGGTCATGGAGTCT and VPX R5825: 5′-CCTGGCACAATGCCTATTCT), Env (7,836–8,403; ENV F7836: 5′-GACGGTCAG-GCCGACACAT and ENV R8403: 5′-TTTCCCTCTGATGATGGGAAG), and Nef (8,822–9,122; NEF F8822: 5′-GGAGGCAAGTGGTCAAAAAG and NEF R9122: 5′-TGGAGTAAATTAGCCCTTCAGT), by using primers with either phage T3 (sense) or T7 (anti-sense) promoter sequences cloned upstream of the viral sequence and pooled into a cocktail at equal concentrations. HIV-1 in situ hybridization was performed as previously described (68).

**Statistics.** Data in this study were analyzed with longitudinal repeated-measures ANOVA, hierarchical linear mixed-effects models (69, 70), standard ANOVA, regression analysis, nonparametric statistical methods, and post-hoc tests. Patients classified in different Fiebig groups (e.g., chronic, FI/II, FIII+, HIV−) were evaluated with respect to the criterion variables (e.g., Ki-67, CD4, MPO). Repeated-measures analyses (in which the “repeated” measurements are recorded for the same patient on more than one occasion) and linear mixed-effects models take into consideration the correlation/covariation of responses within the same patient over time. In addition, linear mixed-effects models account for differing variances in responses in different Fiebig groups. Following initial analyses, a posteriori (post-hoc) contrasts and follow-up, pairwise nonparametric (Wilcoxon) comparisons were performed. In all pairwise contrasts and comparisons,
the distributions of the data in the pair of groups under consideration were evaluated with respect to their homogeneity and normality; the probability value obtained from the most appropriate model (i.e., the model that best satisfied the homogeneity of variance and normality assumptions) was selected. Compounding type I error rates for post-hoc comparisons were controlled through the use of the Benjamini-Hochberg correction (69). Probability values and adjusted probability values of less than 0.05 ($P < 0.05$) were considered significant, and values between 0.05 and 0.09 (0.05 < $P < 0.09$) were considered marginally significant. Statistical analyses were performed within the R Statistical Language and Environment (71).

Study approval. The study was approved by the IRBs of Chulalongkorn University, Bangkok, Thailand, and the Walter Reed Army Institute of Research, Rockville, Maryland, USA. All participants gave informed consent.

Author contributions
CD designed and conducted experiments, analyzed data, and wrote the manuscript. AS designed and conducted experiments and analyzed data. LJ conducted experiments and analyzed data. DRM analyzed data. WGA performed statistical analysis. RR participated in the protocol development and data interpretation, managed cohort, and collected data. SP participated in the protocol development and data interpretation, managed cohort, and collected data. NP participated in the protocol development and managed cohort operations in Thailand. RD designed and conducted experiments and analyzed data. JMM analyzed data and wrote the manuscript. IS analyzed data and wrote the manuscript. MR participated in the protocol development, designed clinical study, and managed operation of US Military HIV Research Program studies. JHK participated in the protocol development, designed clinical study, and managed RV254 studies. TWS analyzed data and wrote the manuscript. PH analyzed data, managed US cohort, and wrote the manuscript. JDL analyzed data and wrote the manuscript. JA participated in the protocol development, designed clinical study, managed RV254 studies, coordinated research studies, and wrote the manuscript. JDE conceived, designed, and coordinated research studies; conducted experiments; analyzed data; and wrote the manuscript.

Acknowledgments
We thank our study participants and staff from the Thai Red Cross AIDS Research Centre and the Silom Community Clinic in Bangkok for their valuable contributions to this study. SEARCH is a research collaboration between the Thai Red Cross AIDS Research Centre (TRCARC), the University of Hawaii, UCSF, and the Department of Retrovirology, US Army Medical Component, Armed Forces Research Institute of Medical Sciences (Yuwadee Phuang-Ngren, Chayada Sajjawerawan, Rapee Trichavaroj, Robert O’Connell, Nantana Tantibul, Siriwan Akapirat, Surat Jongsrakhaitae). The empirical component of this study was funded by the US Military HIV Research Program, Walter Reed Army Institute of Research, Rockville, Maryland, USA, under a cooperative agreement (W81XWH-07-2-0067) with the Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. at the US Department of Defense. The scientific component of this study was funded in part with federal funds from the National Cancer Institute, NIH, under contract no. HHSN26120080001E, and the Delaney AIDS Research Enterprise (U19AI096109). The work of I. Sereti was supported by the intramural research program of National Institute of Allergy and Infectious Diseases/NIH. We also thank the UCLA Center for AIDS Research (CFAR) Mucosal Immunology Core Laboratory, funded by UCLA CFAR grant 5P30 AI028697, for their support and guidance regarding the isolation of mucosal mast cells. We thank the members of the Pathology Histology Laboratory of Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., for their service. The RV254/SEARCH 010 and RV304/SEARCH 013 study groups include Praphan Phanuphak, Nipat Tearatukulsarn, Eugene Kroon, Donn Colby, Duangthathai Suttichom, Somprarthana Rattanamee, Peeriya Pruksakaew, Somporn Tipsuk, Putthachard Karnsomlap, Sasiwimol Uboiyam, and Pacharin Eamyoung from SEARCH/TRCARC/HIV-NAT. See Supplemental Acknowledgments for consortia details (supplemental material available online with this article; doi:10.1172/jci.insight.87065DS1). The content of this publication does not necessarily reflect the views or policies of the US Army, the National Cancer Institute, the US Department of Defense, the Department of Health and Human Services, and the US Centers for Disease Control and Prevention nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.
33. Sankaran S, et al. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is
69. Klipper-Aurbach Y, et al. Mathematical formulae for the prediction of the residual beta cell function during the first two years
